首页> 中文期刊> 《中国药业》 >4种肿瘤标志物联合检测对原发性肝癌的早期诊断价值

4种肿瘤标志物联合检测对原发性肝癌的早期诊断价值

         

摘要

原发性肝癌(PHC)是目前致死率最高的恶性肿瘤,在全球范围内致死率有逐年上升的趋势。目前本病乏有效的早期监测指标,确诊时已多属中、晚期,延误了最佳治疗时机。该文从原发性肝癌的早期诊断出发,论述联合检测血清甲胎蛋白(AFP)、甲胎蛋白异质体3(AFP - L3)、高尔基体糖蛋白73(GP73)和α- L -岩藻糖苷酶(AFU)在诊断 PHC 中的价值,为原发性肝癌的早期诊断提供参考。%Primary hepatic cancer (PHC) is currently one of the highest mortality of malignant tumor in the world, its fatality rate demonstrates the rising trend year by year. At present, PHC is lack of the early effective monitoring index, when definitely diagnosing, HPPC is already at the middle and advanced stage, which delays the best treatment opportunity. This review focuses on the value of AFP, AFP - L3, GP73 and AFU for the diagnosis of PHC from its early diagnosis and provides reference for the early diagnosis of HPC.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号